Clinical trial
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With…
NCT05362058 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT05362058 |
|---|---|
| Title | A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
| Official title | A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes |
| Acronym | QWINT-2 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Insulin Efsitora Alfa, Insulin Degludec |
| Enrollment | 928 |
| Start date | Jun 3, 2022 |
| Primary completion | Apr 10, 2024 |
| Completion | Apr 10, 2024 |
| First posted | May 5, 2022 |
| Last update posted | May 16, 2025 |
| Countries | Brazil, Canada, China, Czechia, Germany, Greece, Japan, Mexico, Puerto Rico, South Korea, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: